These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 20839307)

  • 1. Defining disease-modifying therapies for PD--a road map for moving forward.
    Olanow CW; Kieburtz K
    Mov Disord; 2010 Sep; 25(12):1774-9. PubMed ID: 20839307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroprotection in Parkinson's disease: clinical trials.
    Stocchi F; Olanow CW
    Ann Neurol; 2003; 53 Suppl 3():S87-97; discussion S97-9. PubMed ID: 12666101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics.
    Olanow CW; Hauser RA; Jankovic J; Langston W; Lang A; Poewe W; Tolosa E; Stocchi F; Melamed E; Eyal E; Rascol O
    Mov Disord; 2008 Nov; 23(15):2194-201. PubMed ID: 18932271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Why have we failed to achieve neuroprotection in Parkinson's disease?
    Olanow CW; Kieburtz K; Schapira AH
    Ann Neurol; 2008 Dec; 64 Suppl 2():S101-10. PubMed ID: 19127580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical measures of progression in Parkinson's disease.
    Poewe W
    Mov Disord; 2009; 24 Suppl 2():S671-6. PubMed ID: 19877235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation.
    During MJ; Kaplitt MG; Stern MB; Eidelberg D
    Hum Gene Ther; 2001 Aug; 12(12):1589-91. PubMed ID: 11529246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Obstacles to the development of a neuroprotective therapy for Parkinson's disease.
    Stocchi F; Olanow CW
    Mov Disord; 2013 Jan; 28(1):3-7. PubMed ID: 23390094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. "Disease-modification" trials in Parkinson disease: target populations, endpoints and study design.
    Rascol O
    Neurology; 2009 Feb; 72(7 Suppl):S51-8. PubMed ID: 19221315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical neuroprotection in Parkinson's disease - still waiting for the breakthrough.
    Löhle M; Reichmann H
    J Neurol Sci; 2010 Feb; 289(1-2):104-14. PubMed ID: 19772974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are delayed-start design trials to show neuroprotection in Parkinson's disease fundamentally flawed?
    Clarke CE
    Mov Disord; 2008 Apr; 23(6):784-9. PubMed ID: 18175348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The significance of defining preclinical or prodromal Parkinson's disease.
    Olanow CW; Obeso JA
    Mov Disord; 2012 Apr; 27(5):666-9. PubMed ID: 22508285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The clinical progression of Parkinson's disease.
    Poewe W; Mahlknecht P
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 4():S28-32. PubMed ID: 20123553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Are growth factors the answer?
    Ramaswamy S; Kordower JH
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 3():S176-80. PubMed ID: 20082985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical approaches to the development of a neuroprotective therapy for PD.
    Olanow CW; Kieburtz K; Katz R
    Exp Neurol; 2017 Dec; 298(Pt B):246-251. PubMed ID: 28622912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome measures for clinical trials in Parkinson's disease: achievements and shortcomings.
    Marras C; Lang AE
    Expert Rev Neurother; 2004 Nov; 4(6):985-93. PubMed ID: 15853525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early pharmacologic treatment in Parkinson's disease.
    Hauser RA
    Am J Manag Care; 2010 Mar; 16 Suppl Implications():S100-7. PubMed ID: 20297870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Washout and delayed start designs for identifying disease modifying effects in slowly progressive diseases using disease progression analysis.
    Ploeger BA; Holford NH
    Pharm Stat; 2009; 8(3):225-38. PubMed ID: 19025967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A "cure" for Parkinson's disease: can neuroprotection be proven with current trial designs?
    Clarke CE
    Mov Disord; 2004 May; 19(5):491-8. PubMed ID: 15133811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can we achieve neuroprotection with currently available anti-parkinsonian interventions?
    Olanow CW
    Neurology; 2009 Feb; 72(7 Suppl):S59-64. PubMed ID: 19221316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What's in the pipeline for the treatment of Parkinson's disease?
    Sommer DB; Stacy MA
    Expert Rev Neurother; 2008 Dec; 8(12):1829-39. PubMed ID: 19086879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.